Across TCGA pan-cancer cohorts, NCAN mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated NCAN data layer compared with 26 for mass-spec protein and 10 for mutation status.
The strongest signal is observed in glioblastoma multiforme (GBM), where higher NCAN mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated NCAN expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.
GBM are the cancer types where NCAN mass-spec protein most reproducibly stratifies survival.